Skip to main content

ADIAL PHARMACEUTICALS, INC.

corporate_fare Company Profile

ADIAL PHARMACEUTICALS, INC.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ADIL - Latest Insights

ADIL
Apr 29, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
8
Adial Files New Patent Application for AD04, Targeting Market Exclusivity Through 2045
Sentiment: Positive
View Wiseek Article
ADIL
Apr 22, 2026, 9:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
AD04 Manufacturing Success Paves Way for Phase 3 Clinical Batches
Sentiment: Positive
View Wiseek Article
ADIL
Apr 09, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
7
Adial Pharmaceuticals Grants Significant Equity Awards to Executives and Directors Amidst Going Concern Doubts
Sentiment: Neutral
View Wiseek Article
ADIL
Mar 24, 2026, 9:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
Bipartisan Bill to Expand Veteran Access to AUD Therapies Introduced, Benefiting Adial's AD04
Sentiment: Positive
View Wiseek Article
ADIL
Mar 06, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Details Positive AD04 Regulatory Progress, Streamlined Phase 3 Path, and 2025 Financials
Sentiment: Positive
View Wiseek Article
ADIL
Mar 06, 2026, 8:00 AM EST
Source: GlobeNewswire
Importance Score:
9
Adial Pharmaceuticals Advances AD04 to Phase 3, Citing FDA Alignment and Potential for Single Pivotal Study
Sentiment: Positive
View Wiseek Article
ADIL
Mar 05, 2026, 5:05 PM EST
Source: Wiseek News
Importance Score:
8
Adial Pharma's Cash Runway into H2 2026 Raises Funding Concerns for Pivotal Trials
Sentiment: Negative
View Wiseek Article
ADIL
Mar 05, 2026, 5:03 PM EST
Filing Type: 10-K
Importance Score:
9
Annual Report Reveals Substantial Doubt on Going Concern, New Nasdaq Delisting Threat Looms
Sentiment: Negative
View Wiseek Article
ADIL
Mar 03, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Secures Exclusive European Partnership Framework for AD04, Valued at Up to $60M
Sentiment: Neutral
View Wiseek Article
ADIL
Feb 24, 2026, 9:06 AM EST
Filing Type: 8-K
Importance Score:
7
Adial Pharmaceuticals Regains Nasdaq Compliance Following Reverse Stock Split
Sentiment: Positive
View Wiseek Article
ADIL
Feb 04, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Adial Pharmaceuticals Implements 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
ADIL
Jan 06, 2026, 4:15 PM EST
Filing Type: DEF 14A
Importance Score:
8
Shareholder Vote Critical for $4.3M Warrant Exercise, Significant Dilution Expected
Sentiment: Neutral
View Wiseek Article